CD47 and atherosclerosis: Reducing the “do not eat me” signal is a new strategy for atherosclerosis treatment, with some drugs already researched or approved for clearing ACs, such as CD47 antibodies and PD1-/PD-L1 antibodies (Chen et al., 2021).